Category Archives: pricing

UK’s Controversial Cancer Fund Boosted — But What’s the Long-Term Plan?

By Leela Barham. The English Cancer Drugs Fund (CDF), set up to provide funding for those products that the National Institute for Health and Care Excellence (NICE) has not recommended for use or where their guidance isn’t yet available, remains controversial. Initially penciled for closure in 2014, it is now planned to run to 2016. […]
Also posted in Europe, Guest Blog, Op-Ed | Tagged , , , , , , | Leave a comment

Europe: More Direct-Acting Antivirals, More Controversy

The storms raging across Europe—and beyond—over the pricing of new hepatitis C treatments have been intensified by the European Union’s approval last week of the latest directly-acting antiviral, Bristol-Myers Squibb’s Daklinza (daclatasvir). Just two months after the European Medicines Agency gave a positive opinion on the drug, the formal authorization was delivered for use in […]
Also posted in Europe, Global, Guest Blog, Op-Ed, Regulatory | Tagged , , , , , , | Leave a comment

Pharmaceutical Care Management Association Releases Hep C Medicare Part D Impact Study

As the controversy over Sovaldi’s $84,000 per therapy cost continues to build, the Pharmaceutical Care Management Association has released a study on the impact of the new Hepatitis C drugs on the overall costs to the US Medicare Part D pharmaceutical program (http://www.pcmanet.org/images/stories/uploads/2014/partdpremiumstudymilliman.pdf)
Also posted in healthcare | Tagged , , , , | Leave a comment

The Market Will Demand a Cheaper Alternative to Sovaldi

A new report from Frost & Sullivan forecasts “robust demand” for HCV antivirals, with several strong competitors “maneuvering aggressively” to narrow the market gap by introducing a treatment that can outdo Gilead’s Sovaldi.
Also posted in healthcare, Strategy | Tagged , , , | Leave a comment

CMOs Take a Hit as Payers Refuse to Cover New Drugs

By Jim Miller. The value of the customer relationship to a CMO is a function of two variables: unit volume and price per unit. Both variables are contentious issues: bio/pharmaceutical companies are putting enormous pressure on their CMOs for lower prices, while their inability to deliver forecasted volumes often means lost revenues for CMOs as […]
Also posted in Europe, Global, Guest Blog | Tagged , , , | Leave a comment
  • Categories

  • Meta